Immunotherapy Indications for Parotid Melanoma

Primary Treatment Settings

The American Society of Clinical Oncology recommends anti-PD-1 monotherapy (pembrolizumab or nivolumab) as the preferred first-line treatment for patients with unresectable or metastatic parotid melanoma, due to its durable long-term survival benefits 1, 2
Combination immunotherapy with ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can be used for metastatic disease, though this carries higher toxicity 1, 3

Adjuvant immunotherapy with nivolumab or pembrolizumab is indicated for completely resected Stage IIB, IIC, Stage III, or Stage IV parotid melanoma, aiming to reduce recurrence risk in high-risk patients following surgical resection 1, 2

For Stage III (Regional Lymph Node Involvement), after complete resection including lymphadenectomy if indicated, proceed with adjuvant anti-PD-1 immunotherapy 1
For Stage IV (Distant Metastases) or unresectable disease, first-line treatment is anti-PD-1 monotherapy (pembrolizumab or nivolumab) 1, 2
Alternative first-line treatment for Stage IV or unresectable disease is combination ipilimumab/nivolumab for patients who can tolerate increased toxicity 1, 3

BRAF mutation testing should be performed for Stage III-IV disease to determine eligibility for targeted therapy alternatives, though immunotherapy remains preferred first-line in most cases 1, 3
No biomarker selection is required for anti-PD-1 monotherapy in the metastatic setting for melanoma 1

Patients with active autoimmune disease requiring systemic immunosuppression should be evaluated as a relative contraindication to immunotherapy 1, 4
Patients must have adequate performance status to tolerate immune-related adverse events and sufficient organ function to manage potential immune-mediated toxicities 1, 4

Do not delay immunotherapy initiation while waiting for molecular testing results in clearly metastatic disease, as checkpoint inhibitors do not require mutation-specific selection 1, 3
Do not use traditional RECIST criteria alone to assess response; immune-related response criteria should be employed as tumor regression may occur over prolonged periods 4, 5, 6
Do not discontinue therapy prematurely for apparent progression without considering pseudoprogression, which can occur with immunotherapy 5, 6
Be prepared to manage immune-related adverse events aggressively, as these can affect any organ system and may require corticosteroids or other immunosuppression 1, 4